BEYONDSPRING INC

BYSINASDAQ

🏆 #4632 by market capEarnings Nov 12US Equity

$0.78▼ $0.23 (−29.21%)

Market closed · at close

🔔

Track BYSI

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 29.2%

7d▲ 6.2%

14d▲ 5.2%

30d▲ 19.2%

ytd▼ 51.6%

1y▼ 57.1%

🏦Market Cap

$32M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Good

Trading Snapshot

Day Range: $0.76 – $0.78
52-Week Range: $0.57 – $2.44
Volume: $3.73B
Avg Volume: $4.29B
Shares Outstanding: 41.1M
Next Earnings: Dec 16, 2026

Fundamentals Snapshot

Annual Revenue: $4M
Last Q Revenue: $1M
P/E Ratio: -4.7
P/S Ratio: 0.0x
EPS (TTM): $-0.16
Dividend Yield: 0.00%
Dilution (1yr): +1.7%

Why Investors Own BYSI

✓High-growth profile — revenue up +15.6% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BEYONDSPRING INC

BYSI

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$9M▲ +2.2% YoY

Free Cash Flow

−$20M▲ +20.4% YoY

Shares Outstanding

40.4M▲ +1.7% YoY

Net Cash

$7M▲ +$5M YoY

StockOtter · stockotter.space

About BEYONDSPRING INC

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

🦦